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Abstract Iron overload used to be considered rare in
hemodialysis patients but its clinical frequency is now
increasingly realized. The liver is the main site of iron
storage and the liver iron concentration (LIC) is closely
correlated with total iron stores in patients with secondary
hemosideroses and genetic hemochromatosis. Magnetic
resonance imaging is now the gold standard method for
LIC estimation and monitoring in non-renal patients.
Studies of LIC in hemodialysis patients by quantitative
magnetic resonance imaging and magnetic susceptometry
have demonstrated a strong relation between the risk of
iron overload and the use of intravenous (IV) iron products
prescribed at doses determined by the iron biomarker cut-
offs contained in current anemia management guidelines.
These findings have challenged the validity of both iron
biomarker cutoffs and current clinical guidelines, espe-
cially with respect to recommended IV iron doses. Three
long-term observational studies have recently suggested
that excessive IV iron doses may be associated with an
increased risk of cardiovascular events and death in
hemodialysis patients. We postulate that iatrogenic iron
overload in the era of erythropoiesis-stimulating agents
may silently increase complications in dialysis patients
without creating frank clinical signs and symptoms. High
hepcidin-25 levels were recently linked to fatal and non-
fatal cardiovascular events in dialysis patients. It is there-
fore tempting to postulate that the main pathophysiological
pathway leading to these events may involve the pleio-
tropic master hormone hepcidin (synergized by fibroblast
growth factor 23), which regulates iron metabolism.
Oxidative stress as a result of IV iron infusions and iron
overload, by releasing labile non-transferrin-bound iron,
might represent a ‘second hit’ on the vascular bed. Finally,
iron deposition in the myocardium of patients with severe
iron overload might also play a role in the pathogenesis of
sudden death in some patients.
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Almost all hemodialysis patients treated with
erythropoeisis-stimulating agents receive parenteral
(intravenous) iron to ensure sufficient available iron
during therapy.
Until recently, iron overload was considered
exceptional in dialysis patients in the era of
erythropoeisis-stimulating agents. Quantitative
hepatic magnetic resonance imaging is now the gold
standard for iron store estimation and monitoring in
non-renal-patients with secondary hemosideroses
and genetic hemochromatosis.
Recent hepatic magnetic resonance imaging studies
of dialysis patients revealed a high frequency of iron
overload and suggest a strong link between the
cumulative dose of intravenous iron and the risk of
hemosiderosis. The potential iron overload toxicity is
now one of the most controversial topics in the
management of anemia in dialysis patients.
1 Introduction
Routine use of recombinant erythropoeisis-stimulating
agents (ESA) over the past three decades has enabled
anemia to be partially corrected in most patients with end-
stage renal disease (ESRD), thereby improving their
quality of life and reducing the need for blood transfusion
[1]. ESA use frequently leads to iron deficiency, owing to
massive transfer of stored iron to erythroid progenitor cells
[2], inadequate iron mobilization from repleted storage
sites (resulting in functional iron deficiency), and blood
loss related to hemodialysis itself, and also to routine blood
sampling for laboratory tests and occult fecal bleeding
owing to uremic enteropathy [1–3]. In fact, most ESA-
treated hemodialysis patients receive parenteral iron to
ensure sufficient available iron before and during ESA
therapy [3, 4]. Therefore, the twin risks of iron deficiency
and iron overload must be tightly controlled in dialysis
patients on iron therapy. Significantly, most studies pub-
lished in the last two decades have focused on the detection
and treatment of iron deficiency in dialysis patients, while
very few have dealt with iron overload [3, 5]. Thus, until
recently, iron overload among dialysis patients was widely
considered to be more prevalent during the pre-ESA era,
when blood transfusion was often used to treat anemia and
intravenous iron was given without concomitant ESA. As a
result, iron overload was considered rare or exceptional in
the ESA era, yet it is now increasingly recognized as a
problematic clinical issue [3, 6–9]. The liver is the main
site of iron storage, and the liver iron concentration (LIC)
is closely correlated with total body iron stores in patients
with secondary forms of hemosiderosis such as thalassemia
major, sickle cell disease, and genetic hemochromatosis
[10]. Hepatic magnetic resonance imaging (MRI) is now
the gold standard for iron store estimation and monitoring
in patients with secondary hemosideroses and genetic
hemochromatosis [10]. Recent quantitative magnetic sus-
ceptometry and MRI studies of dialysis patients suggest a
strong link between the cumulative dose of intravenous
(IV) iron and the risk of iron overload, and also challenge
both iron biomarker cutoffs and clinical guidelines, espe-
cially with respect to recommended iron doses [8, 11].
Three epidemiological studies recently suggested that
excessive IV iron may increase mortality and cardiovas-
cular events in hemodialysis patients [12–14]. These find-
ings have led to editorials and position articles highlighting
the potential dangers of excessive use of IV iron products
[9, 15, 16] and the inadequacy of guidelines proposed by
KDIGO-2012 (Kidney Disease Improving Global Out-
comes) and the iron biomarker targets set by KDOQI-2006
(Kidney Disease Outcomes Quality Initiative) and the
EDTA-ERA-2009 (European Dialysis and Transplant
Association-European Renal Disease) in protecting ESRD
patients from iron overload [4, 17, 18]. They also con-
tributed greatly to the organization of the KDIGO Con-
troversies Conference on iron management in chronic
kidney disease (CKD), which took place in San Francisco
on March 27–30, 2014 [19]. This conference was attended
by nephrologists, hematologists, hepatologists, and spe-
cialists in iron metabolism. Its consensus statements rec-
ognized the ‘iron overload’ entity in hemodialysis patients
and called for a specific research agenda [19]. Finally, in
June 2015, the Dialysis Advisory Group of the American
Society of Nephrology published an aggiornamento on
high ‘blind’ use of IV iron in hemodialysis patients [20]. It
is noteworthy that the Japanese Society for Dialysis had
already proposed, some years ago, that dialysis patients
should receive a minimal amount of IV iron (no more than
650 mg in the induction phase), only if they had true iron
deficiency (ferritin \100 lg/L), and also warned against
maintenance intravenous iron therapy for fear of toxicity
[21]. This general review examines recent findings in this
field, lying at the crossroads of iron metabolism and drug
toxicity, nephrology, hematology, hepatology, and radiol-
ogy, and their potentially important implications for the
management and well-being of some 2 million hemodial-
ysis patients worldwide.
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2 Iron Metabolism
Total iron stores average 2.2–3.5 g in healthy women and
3–4 g in men [22]. Nearly two-thirds of this iron is seques-
tered in the hemoglobin molecules of circulating erythro-
cytes and, to a lesser degree, in medullary erythrocytes.
Another 20 % is held in the liver (in hepatocytes andKupffer
cells) or in the reticulo-endothelial system (mainly in splenic
macrophages), predominantly in the form of the iron-storage
protein ferritin (marginally as hemosiderin), while muscle
myoglobin accounts for a further 10 % [22]. Iron-containing
enzymes contain only 1 % of iron stores, and circulating
transferrin-bound iron represents only 0.2 % (3 mg) [22].
Each day, reticulo-endothelial macrophages recycle about
20–30 mg of iron coming from senescent erythrocytes,
covering the 20–30 mg of iron required for normal ery-
thropoiesis [22]. Physiological iron losses are estimated to be
about 1 mg/day (urine 0.1 mg/day; enterocyte desquamation
0.6 mg/day, skin 0.3 mg/day). In women, these losses are
increased by menstruation (the leading cause of iron-defi-
ciency anemia worldwide), pregnancy, and breast-feeding
[23]. Recommended dietary iron intake is about 10 mg/day
(only about 10 % of dietary iron is absorbed), rising to
30 mg/day for pregnant and nursing women [23].
Hepcidin-25 is the master hormone of iron metabolism.
It is synthesized in the liver and acts negatively on both
intestinal iron absorption and iron release from reticulo-
endothelial macrophages and liver cells by reducing the
expression of ferroportin, a protein that regulates iron
export out of these cells [22]. Iron itself and inflammation
(via interleukin-6) enhance hepcidin-25 synthesis, while
anemia, hypoxia, bleeding, iron deficiency, erythropoietin,
and increased medullary erythropoı¨esis all down-regulate
hepcidin-25 synthesis [22]. The mechanism by which ery-
thropoietic stimulation after blood loss down-regulates
hepcidin synthesis was recently linked to a new peptide
hormone, erythroferrone, which is secreted by erythroblasts
and acts directly on the liver [24]. Deficient hepcidin-25
synthesis plays a central role in genetic hemochromatosis,
whereas unregulated hepcidin synthesis is responsible for a
newly discovered genetic (autosomal recessive) form of
iron-deficiency anemia called IRIDA (iron refractory iron
deficiency anemia) owing to a mutation of the
TMPRSS6 gene that encodes matriptase-2 [10, 25]. IRIDA
is refractory to oral iron but responds partially to IV iron
administration [25].
3 Blood Losses Due to Hemodialysis
Blood losses are a major factor in iron deficiency associ-
ated with dialysis but have largely been overlooked since
the advent of ESA and IV iron products. There are three
cumulative sources of blood loss in hemodialysis patients:
(1) the dialysis technique; (2) regular blood sampling for
laboratory tests, and (3) occult intestinal bleeding owing to
uremic enteropathy. Blood losses in this setting have tra-
ditionally been estimated at between 4 and 12 L per year
(2–6 g of iron per year, 1 L of blood containing about
500 mg of iron, but this may be an over-estimation because
of the lower hematocrit of dialysis patients, resulting in a
lower iron content) [26]. This approximation clearly
overestimates dialysis-related blood losses. Moreover, the
vascular access and comorbidities strongly influence the
sources and amount of blood loss.
Blood loss has been estimated at 0.3 mL/session [27]
and 0.9 mL/session [28] with modern dialysis membranes,
and blood-line losses at 0.2 mL/session [27]. Thus,
assuming losses of 1.1 mL per session, annual losses owing
to the hemodialysis technique itself during conventional
hemodialysis (3 sessions/week, 150 sessions/year) repre-
sent about 165 mL (Table 1). With daily dialysis, this
volume reaches between 330 mL (6 sessions/week) and
385 mL (7 sessions/week). At the 2014 Annual Meeting of
the American Society of Nephrology, Japanese researchers
reported similar volumes: residual blood in the tubing set
and dialyser (measured by atomic spectrometry in 238
patients) represented an average loss of 1245 lg of iron per
dialysis session [29].
However, one of the main sources of blood loss in
dialysis units is related to the care of (tunnelized) double-
lumen catheters by nurses applying a universal purge
protocol (7–10 mL of blood in each catheter branch at the
outset of the session), which leads to annual blood loss of
2.4 L. An additional 288 mL should be added for routine
monthly bacterial culture of anticoagulant locks when this
practice is employed. Thus, total annual blood loss linked
to the use of a double-lumen catheter is about 2.7 L
(Table 1) [30]. Note that the use of a recent protocol pro-
posed by Prof. Bernard Canaud, based on a purge of only
2 mL per branch, would reduce catheter-related blood loss
to only 888 mL/year (-77 %) [30]. Finally, sudden
Table 1 Blood losses in hemodialysis patients [30]
Related to the dialytic technique
(membrane ? blood lines)
165 mL of blood/year
Occult gut (micro) bleeding 2257 mL of blood/year
Regular blood sampling for
biological follow-up
428 mL of blood/year
Care of double-lumen catheters 2680 mL of blood/year
In summary (vignette)
Patient with a native fistula 2680 mL of blood/year
Patient with a long-lasting
double-lumen catheter
5320 mL of blood/year
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accidental bleeding owing to insufficient compression or
high internal pressure of a native fistula may cause addi-
tional, severe blood loss [30].
Regular blood sampling is the second major source of
blood loss in this setting. In a recent French survey, routine
blood sampling was quantified at between 350 and
450 mL/year in ten dialysis centers run by the RAMSAY-
Ge´ne´rale de Sante´ healthcare provider [30], a volume close
to that found by Sargent and Acchiardo (368 mL) at the
University of Tennessee in Memphis in 2004 [26, 30]
(Table 1). Blood sampling for routine follow-up has been
estimated at 600 mL/year in Japan [29]. Note that blood
sampling can be markedly increased by participation in
clinical trials and pathophysiological studies.
The third source of blood loss is occult gut bleeding,
which is below the detection limit of classical stool tests.
This is favored by uremic enteropathy, uremic platelet
dysfunction, and anticoagulation of the extracorporeal
circuit [31]. In the 1980s, Rosenblatt and co-workers, using
chromium 51-labeled erythrocytes, quantified fecal blood
loss at 0.83 mL/day in healthy controls, 3.15 mL/day in
non-dialysed CKD patients, and 6.27 mL/day (2.2 L/year)
in hemodialysis patients [31] (Table 1). These losses are
increased by antiplatelet drugs and vitamin K antagonists,
which necessitate the use of higher IV iron dosages to
replenish iron stores (e.g,. 703–961 mg of additional IV
iron per year) [32, 33].
A hemodialysis patient with a native arteriovenous fis-
tula, treated in a non-academic dialysis center without
antiplatelet drugs or vitamin K antagonists, can thus be
expected to lose 2.85 L of blood per year (1.425 g of iron/
year), whereas a patient with the same clinical profile but a
double-lumen tunnelized catheter will lose 5.5 L of blood
or 2.765 g of iron per year. Even this latter figure is far
below the classical estimate of between 2 g and 6 g/year
(Table 1) [30].
4 Intravenous (IV) Products
Iron deficiency is an important clinical concern in CKD
patients, especially hemodialysis patients, as it gives rise to
superimposed iron-deficiency anemia and impairs various
cellular functions. Oral supplementation, in particular with
ferrous salts, is associated with a high rate of gastroin-
testinal adverse effects in this setting and is poorly absor-
bed, a problem that is avoided with IV iron products [30].
Recently, the European Medicines Agency’s Committee
for Medicinal Products for Human Use took measures to
minimize the risk of (rare) allergic reactions to IV iron
products by modifying the summaries of product charac-
teristics, allowing IV iron infusions to take place only in
public or private hospitals, and imposing clinical
monitoring for at least 30 min after the infusions [30].
Seven different IV iron pharmaceuticals are available today
in the USA and Europe and in other industrialized coun-
tries: their main physicochemical and pharmacokinetic
characteristics are summarized in Table 2. The most recent
and stable IV iron complexes (low-molecular-weight iron
dextran, ferric carboxymaltose, iron isomaltoside 1000, and
ferumoxytol) can be given at higher single doses and more
rapidly than older preparations such as iron sucrose
(Table 2) [30, 34]. The larger size of the carbohydrate shell
of some recent IV iron pharmaceuticals (low-molecular
weight dextran and ferumoxytol) increases the risk of
anaphylaxis, although it remains rare [35]. Test doses may
be advisable for low-molecular-weight iron dextran but are
no longer mandatory [30, 34]. Iron supplementation is
recommended for all CKD patients with iron-deficiency
anemia and those who receive erythropoiesis-stimulating
agents, whether or not they require dialysis [4, 17, 18].
Parenteral iron therapy has gained popularity in the
nephrology community in the last 15 years and the IV
route has for many years been the preferred route of
administration to hemodialysis patients because of its
convenience (infusion during dialysis sessions), its supe-
riority over oral preparations for treating true iron defi-
ciency, and its ability to overcome functional iron
deficiency, a very common clinical situation in dialyzed
CKD [1, 4, 17, 18]. Indeed, randomized trials in
hemodialysis patients showed significantly greater increa-
ses in hemoglobin levels with IV iron as compared with
oral iron, and a low rate of treatment-related adverse events
during these albeit short trials [1, 17]. In addition, IV iron
products enable cost savings of about 20–30 % by sparing
expensive ESA products [36]. It is also noteworthy that the
recent meta-analysis performed by the Cochrane network
comparing parenteral vs. oral iron concluded that the 28
included studies (2098 participants) provided strong evi-
dence for larger increases in ferritin (mean difference:
243 lg/L, 95 % confidence interval (CI) 188–297) and
transferrin saturation (mean difference: 10.2 %; 95 % CI
5.5–14.8), together with only a moderate increase in
hemoglobin (mean difference: 0.9 g/dL; 95 % CI
0.44–1.37) in the IV iron-treated groups [37]. The authors
also noted that adverse effects were adequately reported in
only 50 % of included studies and suggested the need for
further studies with patient-centered outcomes to assess the
real benefit of guideline-advocated strategies for reducing
ESA doses and costs through the use of IV iron; they
further underlined the need to prove the lack of serious
adverse effects of these pharmaceuticals [37]. With the
exception of iron gluconate and ferumoxytol, which are
specially indicated in CKD patients with iron deficiency,
IV iron pharmaceuticals are only indicated for use in the
general case of iron deficiency anemia (whatever the
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underlying disease) when oral iron is unavailable, inef-
fective, or poorly tolerated, or as a first-line treatment when
there is a clinical need to rapidly replenish iron stores (iron
sucrose and low-molecular-weight iron dextran) [38].
Moreover, iron overload represents a formal contraindica-
tion to begin or pursue therapy with these IV iron products,
as stressed in the Contraindications or Precautions section
of the summaries of product characteristics [38].
5 Evolving Concept of Iron Therapy
in Hemodialysis Patients over the Past Two
Decades, and the Increased Use of IV Iron
Products Worldwide
When erythropoietin replacement therapy became possible
in the late 1980s, the goal of iron therapy was to maintain
iron stores, allowing true iron deficiency to be prevented,
mainly with oral iron supplements, usually in patients with
serum ferritin levels below 50 lg/L [39, 40]. Parenteral
iron was considered only a second-line option when oral
iron drugs were poorly tolerated or ineffective, or when
severe iron deficiency was present [39–41].
Based solely on bone marrow studies and short-term tol-
erability in controlled trials of IV iron products, recent
guidelines of the Kidney Disease Outcomes Quality Initiative
(KDOQI) in the USA in 2006, endorsed by the European
Renal Best Practice (ERBP) of the European Renal Associa-
tion EDTA-ERA redefine iron deficiency (ferritin\100 lg/L
instead of 50 lg/L) and adopt even higher iron-store repletion
criteria (ferritin target[250 and\500 lg/L) [4, 18].
The KDIGO 2012 guideline set the upper ferritin limit at
500 lg/L for hemodialysis patients, underlined the risk of
functional iron deficiency during ESA treatment, and
emphasized the ability of IV iron to avoid the use of ESA
[17]. It even advocated a trial of IV iron prior to ESA [17].
These clinical guidelines, which are largely followed
and often exceeded by nephrologists worldwide, have
clearly contributed to the excessive use of parenteral iron in
hemodialysis patients [4, 17, 18]. An epidemiological study
of anemia management in American hemodialysis patients,
based on the United States Renal Data System register,
showed that the use of IV iron rose from 64 % of patients
in 2002 to 76 % in 2008, while the infused dose rose from
166 to 216 mg/month over the same period [42]. Yet the
usual monthly dose of IV iron during the first year of
hemodialysis was even higher, ranging from 270 mg to
305 mg/month [42]. Furthermore, the US Food and Drug
Administration modified the ESA label in June 2010,
leading to a rise in the proportion of US patients receiving
IV iron from 57 % in August 2010 to 71 % in August
2011, and to a significant decline in ESA dosages [43]. The
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of patients had values exceeding 800 lg/L [43]. Nearly one
in five dialysis patients received more than 500 mg/month
during this period [43].
Similar trends in the use of IV iron in other industri-
alised countries were recently reported, with the exception
of Japan. Overall, the percentage of patients who received
IV iron rose between 1999 and 2010 from 50 to 71 %
(from 65 to 80 % in Canada; from 55 to 70 % in France,
from 65 to 80 % in Germany, and from 60 to 80 % in the
UK) [44]. Between 1999 and 2010, the mean ferritin level
increased in most countries (from 380 to 450 lg/L in
Canada, from 420 to 580 lg/L in Germany, and from 400
to 500 lg/L in the UK) but remained stable in France
(around 400 lg/L) [44]. In Japan, the proportion of patients
receiving IV iron rose only from 25 to 36 %, while the
mean ferritin level increased only from 280 to 320 lg/L
[44]. Overall, in industrialized countries outside the USA,
the average monthly dose of IV iron infused during
hemodialysis sessions rose by 21 %, from 232 mg/month
in 1992 to 281 mg/month in 2010 [44].
Of note, the recent Dialysis Outcomes and Practice
Patterns Study (DOPPS)-Monitor study (9735 patients in
91 US facilities) showed a decrease in the amount of IV
iron infused, from 280 mg/month in 2011 to
200 mg/month in 2012, with a similar value in 2013 [45].
Of note, there are no data to show that cumulative doses
of IV iron per individual exceed estimated losses. More-
over, the KDIGO controversies conference agenda stressed
the need for studies to quantify blood losses in dialysis
patients, especially from the intestinal tract, in the era of
widespread use of low-molecular-weight heparin antico-
agulation of the extracorporeal circuit, which may reduce
occult gut bleeding, and, at the opposite end of the spec-
trum, in patients on antiplatelet agents and vitamin K
antagonists, who lose more blood [19].
6 Lessons Learned From Hemodialysis-associated
Hemosiderosis in the Pres-ESA Era
The poor prognosis of ESRD in the pre-ESA era, together
with the severity of dialytic complications (especially full-
blown clinical iron overload owing to transfusions and sole
use of IV iron products), provided valuable lessons on the
use of iron supplements, mainly based on autopsy studies
[3]. Indeed, post-mortem studies of dialysis patients with
severe hepatosplenic sideroses in the late 1970s and early
1980s showed abundant iron deposits in the liver, spleen,
adrenal glands, lymph nodes, and lungs, with generally
smaller amounts in the kidneys, pancreas, and heart [46–
48]. The earliest detectable hepatic iron deposits were
found in cells lining the sinusoids and in Kupffer cells [46].
As hepatic siderosis progressed, iron started to appear in
hepatocytes, initially at the periphery of hepatic lobules
close to portal triads and then throughout the lobule [46].
The main iron storage site in the spleen was in the cells
lining the splenic sinusoids, whereas the white pulp was
usually spared [46]. Even massive hepatic siderosis was not
apparently associated with cell damage, although reticulin
and trichrome staining showed a more abundant fibrocon-
nective framework and a loss of liver cells [46–48]. Of
note, liver enzymes were seldom increased in patients with
hepatic siderosis [47] and cirrhosis was rare [46–48].
Indeed, liver biopsy showed focal portal fibrosis in most
patients with marked hemosiderosis [49], suggesting that
the risk threshold for hepatic cirrhosis in iron-overloaded
dialysis patients is high in the absence of coexisting viral
hepatitis [46–49].
Importantly, post-mortem studies showed that iron
overload was strongly linked to blood transfusion and also
to the use of IV iron (high-molecular-weight iron dextran,
Imferon); the closest relationship was between hepatic
siderosis and the use of IV iron [6, 47, 48]. Patients who
received little or no IV iron were usually free of iron
overload, and massive hepatosplenic siderosis was only
seen in patients who had been on dialysis for more than
3 years [6, 47, 48]. Adrenal involvement was observed in
respectively 5 % (11/24) of unselected patients studied by
Pitts et al. [47], compared with 94 % (17/18) of patients
with severe hepatosplenic siderosis studied by Ali [46].
Pancreas involvement was found in only 7/24 patients
(29 %) studied by Pitts and co-workers and in 5/18 patients
(27 %) with severe hepatosplenic siderosis studied by Ali
[46, 47]. Significant iron deposits were found in the heart
of respectively, 16.6 % (4/24) and 22 % (5/22) of unse-
lected patients in the autopsy studies of Pitts [47] and
Gokal [48], but in 44 % (8/18) of patients with severe
hepatosplenic siderosis studied post-mortem by Ali [46].
At that time, one possible strategy to avoid transfusion-
related iron overload in dialysis patients with transfusion-
dependent anemia was to transfuse young rather than
mature erythrocytes [49]. The only available iron chelator
(deferoxamine/Desferal) was advocated to prevent
hemosiderosis and to treat organ dysfunction owing to iron
overload [49].
The arrival of recombinant human erythropoietin in the
early 1990s represented a therapeutic revolution. It allowed
anemia and iron overload to be treated simultaneously by
inducing both massive mobilization of iron stores and
effective phlebotomy (by partial letting of the extracorpo-
real circuit) at the end of the dialysis sessions in patients
who had been rendered non-anemic [50]. The same period
saw the first successful use of non-invasive radiological
tools (quantitative computed tomography) for the diagnosis
of hemodialysis-associated hemosiderosis and for moni-
toring liver iron stores [51].
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Note that this classical (although rare) clinical picture of
hemodialysis-associated hemosiderosis seen during the
pre-ESA era has totally disappeared over the past three
decades in industrialized countries.
7 Non-invasive Imaging of Liver Iron Stores
The liver is the main iron storage site and the LIC gives a very
accurate picture of total body iron stores in patients with
secondary hemosideroses such as thalassemia major, sickle
cell disease, and genetic hemochromatosis [52, 53]. Non-in-
vasive techniques for estimating liver iron stores have been
developed to avoid liver biopsy, including the superconduct-
ing quantum interference device (SQUID), quantitative
computed tomography, and MRI [54, 55]. MRI is now the
preferred technique, because of its reproducibility, sensitivity,
availability, and ability to scan multiple organs in the same
session [55].HepaticMRI is now the gold standardmethod for
estimating and monitoring iron stores in non renal patients,
providing ‘iterative radiological biopsy’ [53, 56].
The LICmay be the best marker of iron overload in ESRD:
hemodialysis patients receiving IV iron in the pre-ESAera had
paradoxically lowbonemarrow iron content in up to one-third
of cases, despite severe hepatosplenic siderosis [6], suggesting
that bone marrow analysis may not accurately quantify iron
stores in dialysis patients, even in the ESA era [6].
SQUID (or magnetic susceptometry) is based on the
magnetic volume susceptibility of paramagnetic ferritin/he-
mosiderin iron in the liver and was validated against percu-
taneous biopsy [55, 56]. SQUID does not distinguish between
ferritin andhemosiderin iron [55, 56].However, thismethod is
not widely available (only five devices worldwide), very
costly (about 1000–1500 euros per exam, and evenmore in the
USA), and is characterized by the lack of calibration homo-
geneity (risk of LIC under-estimation) [55, 56].
Liver quantitative computer tomography has now given
way to MRI [51, 54, 55]. Quantitative MRI is based on the
paramagnetic properties of iron: the magnetic resonance
signal falls as the LIC increases [55]. Like SQUID, MRI
does not distinguish ferritin from hemosiderin iron [55].
The advantages of MRI include its low cost (about 300
euros per exam in Europe), non-irradiating nature, and
availability. In addition, it does not require gadolinium and
thus avoids the risk of gadolinium-associated nephrogenic
fibrosis in CKD patients (a clinical situation mimicking
scleroderma) [55].
There are three MRI modalities for liver iron assay in
non-renal patients: the signal-intensity ratio, R2 relaxom-
etry, and R2* relaxometry [55]. The signal intensity ratio
method was first published in the Lancet in 2004, having
been developed at Rennes University (France) on a 1.5-T
apparatus [57]. This is the method most widely used in
Europe [58]. It was validated in a cohort of 191 patients
with secondary hemosiderosis, genetic hemochromatosis,
and hepatic disorders requiring liver biopsy for biochemi-
cal iron assay [57]. The Rennes University method was
replicated, by comparison with liver biopsy, in three
prospective cohorts in France, the Netherlands, and Spain
[58–60]. It is based on a comparison of liver and muscle
intensities in various sequences (T1, PD, T2, T2?, T2??),
the results being analyzed with an algorithm that chooses
the most sensitive and specific sequence depending on the
severity of iron overload [57]. Free analytical software is
available on the Rennes University website. This method
has a sensitivity of 89 % and a specificity of 80 % for iron
overload disease, and is linear up to 350 lmol/g of dry
liver tissue [57]. An algorithm established by a Spanish
team is required for values exceeding 350 lmol/g of dry
liver tissue [60].
The second MRI method, based on R2 relaxometry, was
developed on a 1.5-T apparatus in Australia in 2005 [61]. It
was validated in a cohort of 105 patients with thalassemia,
genetic hemochromatosis or hepatic disorders who had liver
biopsy [61]. It was also favorably compared to SQUID in 23
patients [62]. This method based on R2/T2 sequences (com-
mercial name Ferriscan) has a sensitivity of 86 % and a
specificity of 88 % for iron overload disease. It is linear up to
700 lmol/g of dry liver, but the apparatusmust be specifically
configured and calibratedwith phantoms [61]. It is principally
used in Australia, New Zealand, and North America.
The third MRI technique for iron-store quantification is
based onR2* relaxometry and can be used on a 1.5 T apparatus
with specific software. This method not only quantifies liver
iron but also detects iron overload in the heart, spleen, and
pancreas in the same session (about 20–30 min) [63]. Its main
limitation is that it has only been validated against a small
number of liver biopsies (22, 30, and 47 patients in the three
available studies) [63–65]. Equations have also been proposed
byWood and by Pennell to transform the results intomilligram
of liver iron [63, 64]. Finally, specific MRI sequences can also
give valuable information on liver fat and dysmorphia.
Normal MRI hepatic iron store values have been
established on the basis of liver biopsy, together with
categories of iron overload reflecting the risk of compli-
cations (Table 3) [10, 55]. According to Rennes Univer-
sity, LIC values between 40 and 100 lmol/g of dry liver
tissue represent mild iron overload, between 101 and
200 lmol/g moderate iron overload, and [201 lmol/g
severe iron overload [57]. As the upper 95 % of LIC in
healthy adults is 32 lmol/g but hepatic MRI only accu-
rately detects liver iron load exceeding 50 lmol/g, the
upper limit of normality has been set at 50 lmol/g for
dialysis patients [8]. Therapeutic proposals for clinically
relevant thresholds of MRI-determined LIC are included in
hepatology and hematology guidelines for iron overload
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diseases; examples include chelation for hemosiderosis and
phlebotomy for genetic hemochromatosis, and also specific
follow-up of target organs (Table 3) [10, 53–56].
There is currently a need to validate these MRI tech-
niques for quantifying liver iron content specifically in
dialysis patients, notably by comparison with liver biopsy.
However, liver biopsy is an aggressive and risky invasive
procedure, especially in frail ESRD patients, and such
studies therefore raise ethical concerns. In our opinion, a
prospective MRI study of dialysis patients requiring liver
biopsy or liver surgery for their usual medical care could
help to fill this knowledge gap.
Radiologists may be solicited in the near future by
nephrology teams requesting quantitative hepatic MRI for
research purposes, and later for diagnosis and follow-up of
iron overload in dialysis patients. Radiologists and nephrol-
ogists should realize that there are marked differences in the
pharmacokinetics of IV iron products, and that they can
interfere with MRI (see Tables 2, 4) [66]. The required time
interval between the last IV iron infusion and MRI ranges
from 1 week (iron sucrose, iron gluconate, iron carboxymal-
tose) to 1 month (low-molecular-weight iron dextran and iron
isomaltoside), 3 months (high-molecular-weight iron dex-
tran) or even6 months (ferumoxytol) if spurious results owing
tomagnetic interference are to be avoided (Table 4) [66]. The
Pharmacological Committee of the European Medicines
Agency modified the summary of product characteristics for
ferumoxytol/Rienso in 2015 after the literature review per-
formed by Rostoker and Cohen, making a 6-month interval
mandatory instead of the previous 3 months [66, 67].
8 Iron Overload in Dialysis Patients in the ESA
Era
Studies using SQUID [11] and more recently quantitative
MRI [8, 68, 69] to estimate LIC in hemodialysis patients
have provided new information on iron metabolism in
advanced CKD and have underlined the potential risk of
hemosiderosis. They also suggest a strong link between the
infused iron dose and the risk of iron overload in this
setting, challenging current guidelines with respect to the
safety of IV iron at high repeated doses [4, 17, 18], as well
as the reliability of iron biomarker cutoffs, and methods for
monitoring iron stores in dialysis patients [8, 9, 15, 16].
Two recent MRI studies focused on iron overload in
hemodialysis patients with serum ferritin levels far above
500 lg/L (the upper limit advocated by KDOQI-2006,
EDTA-ERA-2009, and KDIGO-2012 guidelines): Ferrari
et al. used R2 relaxometry to study 15 Australian patients
with a median ferritin of 782 lg/L and found hepatic iron
overload in two-thirds of cases [68]. Ghoti et al. used
T2*MRI to measure liver and spleen iron content, and to
search for pancreatic and cardiac iron deposits, in 21 iron-
overloaded Israeli hemodialysis patients with serum ferritin
levels over 1000 lg/L [69]. They found hepatic siderosis in
19/21 patients (90 %) and spleen involvement in all 21
patients (100 %) [69]. Because of poor patient compliance
with this specific exam, pancreatic involvement was sought
in only the eight most highly motivated patients and was
found in three cases (37 %) [69]. None of the patients had
an abnormal cardiac R2* but few patients were studied and
no conclusions can thus be drawn on the risk of cardiac
iron deposits in patients with very high ferritin levels [69].
Two studies have analyzed LIC stores, one with SQUID
in 2004 [11] and the other in 2012 with the Rennes
University MRI protocol [8] in cohorts of hemodialysis
patients treated according the KDOQI-2006 [4] and EDTA-
ERBP-2009 guidelines [18] and with optimal ferritin levels
(between 200 and 500 lg/L). Canavese et al used SQUID
to study liver iron stores in 40 Italian patients and found
normal values in 30 % of cases (median ferritin 245 lg/L),
mild iron overload in 32.5% (median ferritin 329 lg/L) and
moderate iron overload in 37.5 % (median ferritin 482 lg/
L) [11]. It was claimed that these findings could not be
extrapolated to the general hemodialysis population
Table 3 Clinically relevant
liver iron cut-offs for secondary
hemosiderosis and genetic
hemochromatosis [3]
Liver iron content (lmol/g)
(mg/g)
Clinical LIC cut-offs for iron-overload diseases
32 lmol/g (1.8 mg/g) 95th percentile of healthy adults
125 lmol/g (7 mg/g) Threshold for increased risk of iron–induced complications and level of
decision for chelation therapy (secondary hemosiderosis) or phlebotomy
(genetic hemochromatosis)
143 lmol/g (7 mg/g) Saturation threshold of the reticuloendothelial system in sickle cell disease
160 lmol/g (9 mg/g) Risk threshold for hepatic fibrosis in sickle cell disease
269 lmol/g (15 mg/g) Risk threshold for hepatic fibrosis and cardiac disease in thalassemia major
331 lmol/g (18 mg/g) Risk threshold for hepatic fibrosis or cirrhosis in patients with genetic
hemochromatosis
LIC liver iron concentration
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because of possibly biased selection of an iron-overloaded
population [70].
Rostoker et al. recently showed hepatic iron overload on
MRI ([50 lmol/g dry weight) in 84 % of 119
stable French hemodialysis patients treated according to
current guidelines; iron overload was mild in 42 patients
(35.3 %), moderate in 22 (18.5 %), and severe
([200 lmol/g dry weight) in 36 (30 %), at levels usually
observed in genetic hemochromatosis (Fig. 1) [8]. MRI
also showed spleen anomalies (a feature of secondary
hemosiderosis) in several patients [8].
In the French cross-sectional study, LIC correlated with
infused iron, hepcidin, and C-reactive protein values in uni-
variate analysis (p\ 0.05, Spearman test) and in binary
logistic regression (p\ 0.05) [8]. No link was found between
the LIC of hemodialysis patients with excessive alcohol
consumption [Alcohol Use Disorders Test (AUDIT) score]
and the major HFE mutation C282Y [8]. As in the SQUID
study by Canavese [11], female individuals had an increased
relative risk of iron overload (3.36; 95 % CI 1.03–10.9) [8].
Eleven patients were closelymonitored during parenteral iron
therapy, showing that the monthly IV iron dose correlated
strongly with both the overall and monthly increases in LIC
(rho = 0.66, p = 0.0306 and rho = 0.85, p = 0.0015,
respectively; Spearman’s test) (Figs. 2 and 3) [8].
In the 33 longitudinally studied patients with iron over-
load, iron stores fell significantly after iron withdrawal or
after amajor reduction in the iron dose [firstMRI: 220 lmol/
g (CI: 60–340); last MRI: 50 lmol/g (CI: 5–210);
p\ 0.0001, Wilcoxon’s paired test] (Fig. 3) [8]. The slope
of the decline in hepatic iron was -17.9 lmol/g dry
weight/month after iron withdrawal, -12.8 lmol/g dry
weight/month after a major iron dose reduction, and
11.9 lmol/g dry weight/month after renal transplantation
[8]. Thus, the frequency of iron overload might be vastly
underestimated in hemodialysis patients receiving both ESA
and IV iron; indeed, most hemodialysis patients receiving
ESA and IV iron supplementation according to current
guidelines appear to have hepatic iron overload in these LIC
imaging studies [8, 11]. We subsequently called for a revi-
sion of iron therapy guidelines for dialysis patients, notably
regarding the amount of IV iron infused and non-invasive
monitoring of iron stores [8, 9, 16]. It also should be noted
that hepatic iron stores measured by MRI are a surrogate
marker with as-yet unproven clinical relevance in dialysis
patients in terms of mortality and morbidity.
These recent LIC imaging studies were performed at
least 1 week [8, 11], 2 weeks [68], or months after the last
iron infusion [69]. These findings reveal true liver iron
thesaurosis and differ markedly from the rapid transient
increase in the exchangeable compartment of iron descri-
bed a few years ago by Beshara and coworkers using
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infusion [71–73]. In a minipig model, a large fraction of
radiolabeled iron-sucrose reached the liver in as little as 30
mins after the infusion, and liver uptake was observed until
10 h; release to bone marrow started after 11 h [71]. In six
CKD patients with iron-deficiency anemia, strong liver
uptake of labelled iron-sucrose started 20–60 min after the
infusion and lasted up to 5 h, with liver release of iron
beginning at the sixth hour [72]. Similar but faster human
liver kinetics has been reported with iron carboxymaltose,
with a smaller fraction (30 %) transiently reaching the liver
[73].
A recent Australian study reported use of the oral iron
chelator deferasirox to treat iron overload in hemodialysis
patients [74]. Classical clinical cases of hemodialysis-as-
sociated hemosiderosis (requiring deferoxamine/Des-
feral) have recently been published by a nephrology team
in Egypt and were attributed to the non use of ESA together
with abundant blood transfusions and IV iron infusions
[75]. This highlights the need (as done for antiretroviral
therapy for AIDS in emerging countries) for pharmaceu-
tical companies and international societies of nephrology
and dialysis to make expensive ESA drugs available to
dialysis patients living in these countries.
It is of note that the safety and efficacy of IV iron
products in dialysis patients, as stated in their respective
labels [38] (e.g., induction phase for the most widely used
pharmaceuticals: iron sucrose 100–300 mg/week for a total
dose of 1–1.2 g, possibly repeated up to 2–2.4 g; iron
carboxymaltose and iron isomaltoside 200 mg/dialysis
session with a cumulative dose of 1–2 g according to the
hemoglobin level and body weight), may be at odds with
the clinical practice of strong iron store repletion, as
advocated by current guidelines (KDOQI 2006, ERBP
2009, KDIGO 2012) [4, 17, 18]. Moreover, most labels
give imprecise information, or none at all, on the mainte-
nance phase; only the French label for iron sucrose (be-
cause of the decentralized EMA approval procedure)
indicates a dose of 2 mg/kg once or twice per month,
guided by careful biological monitoring of iron biomarkers
[38]. This latter point was put forward in 2013 by the
French Medicines Agency (ANSM) after analysing the
publication of Rostoker and co-workers performed in a
dialysis center in the Paris area: ANSM stated that although
hemodialysis patients in this study were correctly treated
according to current guidelines, the iron sucrose doses
clearly exceeded those allowed by the label, underlining an
inconsistency between the French iron sucrose label and
anemia guidelines (KDOQI and ERBP) [8, 76]. Conver-
gently, the Dialysis Advisory Group of the American
Society of Nephrology recently considered that largely
unanswered questions remain concerning the doses of iron
to administer, the optimal dosing regimen, and iron
Fig. 1 Results of a cross-
sectional quantitative magnetic
resonance imaging (MRI) study
of 119 hemodialysis patients
(according to [3] and [8])



























Fig. 2 Correlation between the infused iron dose and hepatic iron
stores in 11 hemodialysis patients studied by quantitative magnetic
resonance imaging (according to [8])
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biomarker targets [20]. Finally, data on the effect of iron
infusion on LIC in dialysis patients studied by MRI are
scarce: only one Australian study reported a mean LIC
increase of 25.4 lmol/g dry weight on R2 relaxometry,
2 weeks after infusion of 10–20 mg/kg iron polymaltose
(Maltofer) to 25 CKD patients, of whom five were on
dialysis; the mean LIC increase at week 12 was 13 lmol
[20].
Further studies were called for by the recent KDIGO
conference on the hypothetical risk of aggravation of liver
diseases (e.g., viral hepatitis B and C, non-alcoholic
steatohepatitis) by iron accumulation in CKD patients, and
even the theoretical risk of liver cancer in hepatitis C virus-
positive patients treated with IV iron [19]. Finally, it is
important to find out whether or not dialysis patients with
functional iron deficiency are more prone to iatrogenic iron
overload than those with true iron deficiency.
9 Morbidity and Mortality Related to Iron
Overload in Hemodialysis Patients
In the pre-ESA era, hemodialysis-associated hemosiderosis
was a rare disorder classically comprising pigmented skin,
cirrhosis, and heart failure associated with multiple endo-
crine disorders. It totally disappeared from dialysis centers
in industrialized countries at least three decades ago but
may again be seen in emerging countries (cf supra) [3, 75].
Genetic hemochromatosis and secondary hemosiderosis
related to hematological disorders are now diagnosed very
early, far before development of any organ dysfunction
[10, 53, 56]. Therefore, iron overload in dialysis patients in
the ESA era might silently increase the burden of com-
plications of dialysed CKD rather than induce a full clinical
picture [3, 10, 16]. Thus, considering the scarcity of cir-
rhosis in historical studies and its slow onset, increased LIC
in dialysis patients must rather be seen as a predictor of
iron-mediated intensification of oxidative stress and
inflammation, and disruption of homeostasis of iron-regu-
lating hormones, that might lead to accelerated morbidity
and mortality in this population.
Three methodologically rigorous observational studies
showed no detrimental impact of high-dose IV iron on
morbidity or mortality in dialysis patients (observation
time after exposure of 1 month (with iterative rolling
periods) in Feldman’s study, two months in Miskulin’s
study, and 3 months in Kshirsagar’s study) [77–79]; three
other epidemiological studies with longer follow-up
(1–2 years) show that excessive IV iron may increase
mortality and cardiovascular events in hemodialysis
patients; in our opinion, the longer follow-up of these latter
studies may explain these discrepancies, and suggest that
excess therapeutic iron may cause chronic cumulative
toxicity if given for long periods [12–14].
In a prospective cohort study conducted in Taiwan, 1239
hemodialysis patients were followed for one year: 583
patients not receiving iron therapy were compared with 656
patients treated with IV ferric chloride hexahydrate [12].
Fig. 3 Time course of hepatic iron stores studied by magnetic
resonance imaging in hemodialysis patients (according to [8]).
a Initial and final hepatic iron concentrations on magnetic resonance
imaging (MRI) in 11 patients receiving iron therapy (median time is
given in abcissa). b Initial and final hepatic iron concentrations on
MRI in 33 patients with hepatic iron overload, after iron withdrawal
(n = 19) or a major iron dose reduction (n = 14) (median time is
given in abcissa)
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The patients receiving IV iron were divided into three
subgroups according the cumulative dose: 40–800 mg/
6 months, 840–1600 mg/6 months, and 1640–2400 mg/
6 months [12]. The two subgroups with the higher cumu-
lative iron doses had higher adjusted mortality [respective
hazard ratios (HRs): 3.1 and 3.7] and more cardiovascular
events (respective HRs: 3.5 and 5.1) than those not
receiving IV iron and those who received less than 820 mg/
6 months (or 136 mg/month) [12].
Kuragano and coworkers prospectively monitored 1086
Japanese hemodialysis patients for 2 years and compared
those on oral iron with those treated with IV iron, divided
into three groups: oral iron plus very-low-dose IV iron,
low-dose IV iron (\200 mg/month) and high-dose IV iron
([200 mg/month) [13]. They observed more cases of acute
cardiocerebrovascular disease (HR: 6.02) and hospitaliza-
tion (HR: 2.77) in the high-dose IV iron group, and
increased risk of infections in both the low (HR: 1.78) and
high (HR: 5.22) IV iron-treated groups [13]. High ferritin
levels (consistently above 100 lg/L, in accordance with
Japanese guidelines [13]) were associated with the risk of
acute cardiocerebrovascular disease (HR: 2.22), infections
(HR: 1.76), and death (HR: 2.28) [13]. Moreover, a cate-
gory switch from low to high ferritin (from less to more
than 100 lg/L) was also associated with an increased risk
of acute cardiocerebrovascular disease (HR: 1.59) and
death (HR: 6.18) [13].
The DOPPS study, using Cox regression models with
multiple adjustments, analyzed associations between IV
iron and clinical outcomes in 32 435 hemodialysis patients
followed for a median of 1.7 years (range 1–2.4) in 12
industrialized countries [14]. The authors found higher
adjusted mortality in patients receiving 300–399 mg/month
(HR: 1.13) and 400 mg/month or more (HR: 1.18) than in
those receiving no iron or 1–99, 100–199, or 200–299 mg
of IV iron/month [14]. Similarly, the risk of hospitalization
was higher (HR: 1.12) in patients receiving 300 mg/month
or more of IV iron as compared with those receiving
100–199 mg/month [14]. Note that the toxic monthly iron
doses found in the DOPPS study are very similar to those
(400 mg/month) shown by Kalantar-Zadeh et al. to be
associated with higher mortality among hemodialysis
patients in the Da Vita cohort published 10 years ago [80].
The result of the Japanese study is in keeping with a
recent US study showing that iron maintenance therapy at
200 mg/month is not associated with an increased short-
term risk of infections, contrasting that encountered with
bolus monthly doses of 700 mg [81].
These latter results are in line with the findings of a
recent controlled trial of IV iron-sucrose versus oral iron in
non-dialyzed CKD patients, showing increased serious
cardiovascular and infectious events in IV iron-treated
patients as compared with those receiving oral iron [82].
We postulate that three mechanisms might act syner-
gistically to increase mortality and cardiovascular events in
iron-overloaded hemodialysis patients, namely elevated
hepcidin levels (synergized by fibroblast growth factor 23
[FGF 23]), increased oxidative stress, and arterial and
cardiac structural changes.
Italian authors recently called for a critical re-evaluation
of hepcidin levels in CKD patients, postulating that hep-
cidin is not intrinsically elevated in hemodialysis patients
but rather reflects poor matching with healthy subjects and
frequently excessive iron stores [83]. These authors pos-
tulated that hepcidin elevation may in fact be a physiologic
defense mechanism against iron overload, and that it is
preserved in patients with renal failure, even in those
maintained on dialysis [83]. Indeed, high hepcidin-25
levels in dialysis patients with severe iron overload found
on MRI have been shown to normalize in parallel with liver
iron stores, supporting the latter hypothesis [8]. As high
hepcidin-25 levels in hemodialysis patients were recently
shown to be related to fatal and nonfatal cardiovascular
events, the main physiopathological pathway linking these
events to iron overload might involve the pleiotropic
effects of hepcidin-25 [84], possibly in synergy with FGF
23, which was recently shown to be induced by iron
infusions and to exert cardiac toxicity [85, 86].
Oxidative stress, usually encountered in ESRD [87] and
provoked by IV iron infusions [16] and iron overload
(mediated by the release of labile, non-transferrin-bound
iron) [88], might also adversely affect the vascular bed and
act as a ‘second hit’. In the dialysis population, excess iron
might also play a direct role in cardiovascular complica-
tions by impairing endothelial function, as shown in
patients with hereditary hemochromatosis [89], and also by
directly favoring atherosclerosis [90, 91]. Conversely,
taking into account data from post-mortem studies in the
pre-ESA era, we suspect that myocardial iron deposits in
heavily iron-overloaded dialysis patients might also play a
paramount role in dialysis-related cardiovascular morbidity
and mortality, especially sudden death [46–48 Thus, it is
our opinion that well-powered cardiac T2*MRI studies are
urgently needed in this subset of patients.
Beside these detrimental effects on the cardiovascular
system and mortality, iron overload might affect several
lineages of immune cells, leading to an increased risk of
infection, as shown in some epidemiological studies: these
effects could include CD4? T-cell depletion associated
with shortened cell lifespan, CD8? CD28- T-lymphocyte
expansion, impaired phagocytic activity, and microbial
killing of polymorphonuclear leukocytes and monocytes
[92]. In addition, because iron is an essential element for
bacterial multiplication and virulence, iron overload owing
to high doses of IV iron may increase the risk and severity
of infections. Iron overload might also affect glucose
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regulation by inducing apoptosis of insulin-secreting pan-
creatic beta cells [93]. About 40 % of dialysis patients
worldwide are diabetic, and even a slight increase in iron
stores has been suggested to play a role in the progression
of macrovascular and microvascular complications of dia-
betes [94]. Diabetic dialysis patients might thus have a
higher risk of complications from iron overload.
From a philosophical point of view, as the average life
expectancy of dialysis patients in industrialized countries is
about 4 years, some nephrologists have raised the fair
question as to whether or not exposed patients will live
long enough to develop organ failure from iron overload.
We clearly are lacking the data necessary to answer this
question. On the other hand, as postulated above, iron
overload may act by disrupting homeostasis of hepcidin
and FGF 23 (acting as a second hit) and increase the burden
of cardiovascular diseases in diabetic patients (who now
represent about 40% of dialysis patients) and patients with
widespread atheroma disease (about 20% of old non dia-
betic patients). Finally, the question of long-term exposure
to excessive iron may apply to this subset of young dialysis
patients who have repeated graft failure, a relatively short
time free of dialysis, and a long cumulative dialysis vintage
(one or two decades or even more).
10 Preventing Iron Overload in Dialysis Patients
Iron overload in hemodialysis patients has been favored by
reimbursement policies in the USA and many other industri-
alized countries, which have led to a dramatic increase in the
use of IV iron in an attempt to avoid the high costs of ESA [9,
20]. The situation has been compounded by excessively high
recommended doses of IV iron and, possibly, by erroneous
iron biomarker targets which lead to supraphysiological iron
stores [8, 9]. In addition, nephrologists have come to fear the
adverse effects of ESA while wrongly believing that iron IV
products are nontoxic [20]. Major changes in the approach to
iron therapy have occurred very recently. First, the KDIGO
Controversies Conference on Iron Management in Chronic
Kidney Disease, which took place in San Francisco in March
2014, recognized the entity of iron overload in hemodialysis
patients (together with other adverse effects) and called for a
research agenda on this topic [19]. Second, the Dialysis
Advisory Group of the American Society of Nephrology
proposed an aggiornamento on the policy of high ‘blind’ use
of IV iron products in hemodialysis patients [20]. TheDialysis
Advisory Group of the American Society of Nephrology has
engaged in a profound and frank debate that has greatly con-
tributed to understanding and overcoming this possible
ongoing epidemic of iron overload in dialysis patients [9, 20].
Recent reviews of anemia and iron therapy inCKD, published
in hematological and nephrology journals, have given a more
balanced view, emphasizing not only the benefits but also the
risks, including the danger of iron overload [95–98].
Quantitative MRI, which allows safe, non-invasive,
repeated ‘radiological liver biopsy’ has recently been
advocated by French [3, 30, 99] and Japanese authors [100]
for routine iron-store monitoring of iron-treated dialysis
patients (and also non renal patients on long-term treatment
with IV iron products) [99]. Recent cohort studies of
hemodialysis patients, combining quantitative MRI with
data-mining and classical statistical methods, could yield
both non-toxic doses of IV iron and accurate target values
for biological markers of iron metabolism, thereby
improving the safety of parenteral iron products in dialysis
patients [101, 102]. The aim of the first study, based on
decision-tree learning and on MRI determination of hepatic
iron content, was to identify a noxious pattern of parenteral
iron administration in a prospective cohort of 199
hemodialysis patients treated for anemia with parenteral
iron-sucrose and an ESA, in keeping with current clinical
guidelines [101]. Hepatic iron stores were measured
blindly by T1 and T2* contrast MRI, without gadolinium,
coupled with CHi-squared automatic interaction detection
(CHAID) analysis [101]. The CHAID algorithm split the
patients according to the monthly IV iron dose, with a
single cutoff of 250 mg/month. The odds ratio for hepatic
iron overload on MRI was 3.9 (95 % CI: 1.81–8.4) with
more than 250 mg of IV iron/month versus less than
250 mg/month [101]. This MRI study suggests that the
standard maximal monthly IV iron dose should be lowered
to 250 mg to lessen the risk of iron overload in dialysis
patients [12–14]. The second study analyzed correlations
between iron biomarkers and LICs measured blindly by
quantitative MRI, and examined their accuracy for the
diagnosis of iron overload in a prospective cohort of 212
hemodialysis patients treated with parenteral iron-sucrose
and ESA for anemia, in keeping with current guidelines;
the relationships were analyzed with Spearman’s coeffi-
cient, logistic regression, and ROC curves [102]. Only
serum ferritin showed a strong correlation with LIC
(rho = 0.52, 95 % CI: 0.41–0.61, p\ 0.0001, Spearman
test). Likewise, in logistic analysis, only serum ferritin
correctly classified the patients into those with normal liver
iron stores (LIC\50 lmol/g) and those with elevated liver
iron stores (LIC[50 lmol/g) (odds ratio 1.007; 95 % CI:
1.004–1.010) [101]. Serum ferritin was the most discrimi-
natory iron biomarker in ROC curve analysis
(AUC = 0.767; 95 % CI: 0.698–0.835). The optimal serum
ferritin cut-offs were 160 lg/L for LIC[ 50 lmol/g (mild
overload) and 290 lg/L for LIC [200 lmol/g (severe
overload) [102]. Having used quantitative MRI for more
than 10 years in more than 250 dialysis patients at Claude
Galien hospital in France, we have found a divergence
between ferritin and LIC values in patients with
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inflammatory markers (e.g., high serum ferritin with nor-
mal or mildly increased LIC), a common situation partially
related to the increasing prevalence of multiple comor-
bidities and medical complications in the population of
hemodialysis patients; this is in line with ferritin modula-
tion by inflammation and its role as an acute-phase reactant
(unpublished data).
These results also suggest that ferritin targets in current
guidelines (KDIGO, KDOQI, ERBP) should be lowered to
avoid iron overload and its potential harmful effects [102].
The nephrology community is also rediscovering the
smart, cautious Japanese strategy of iron therapy, which
maintain optimal hemoglobin levels (somewhat lower than
in Western countries) with minimal use of IV iron products
and low ferritin levels [21, 103]. It is tempting to speculate
that the better overall survival of Japanese hemodialysis
patients as compared with US and European patients,
which is consistently found (despite multiple adjustments),
might be, at least in part, related to lower use of IV iron
products and, thus, less iron overload.
Major progress in the management of iron status in
dialysis patients may soon come from investigational drugs
that selectively inhibit hypoxia-inducible factor prolyl
hydroxylases (HIF-PH) and stabilize hypoxia-inducible
factor (HIF) [104]. HIF, a key regulatory protein, stimu-
lates erythropoietin and transferrin production, reduces
hepcidin production, and thereby modulates iron absorp-
tion and metabolism [104]. HIF-PH may also protect
against ischemia-reperfusion damage) [104]. Phase III tri-
als of HIF-PH in dialysis patients seek to manage iron
stores very conservatively and cautiously, using oral iron
and adopting a target ferritin value of at least 100 lg/L.
Beside HIF stabilizers, iron administration via the dialy-
sate (ferric pyrophosphate citrate/Triferic) and a ferric
citrate-based phosphate binder (Auryxia) are new thera-
peutic options for compensating iron deficiency related to
blood loss in hemodialysis patients and for providing the iron
required for erythropoiesis [105–108]. Ferric pyrophosphate
citrate/Triferic rapidly delivers iron directly and safely to
the bone marrow (5–7 mg iron) during hemodialysis ses-
sions via the dialysate, efficiently matching the amount of
iron required by ESA to generate red blood cells, without
increasing ferritin levels [105]. The new phosphate binder
composed of ferric citrate (Auryxia), beside its ability to
chelate intestinal phosphate, strongly reduces the need for IV
iron in dialysis patients, thus lowering the risk of iatrogenic
iron overload and re-establishing oral iron as an efficient and
well-tolerated source [106–108]. However, the Precautions
section of the summary of product characteristics for
Auryxia states that iron citrate may be absorbed probably
via disrupted intestinal tight junctions in uremic patients,
meaning that physiological regulation of iron absorption
may be overstepped, resulting in iron overload [109–112].
Careful monitoring of iron stores in dialysis patients on
Auryxia is therefore recommended by the US Food and
Drug Administration [109].
Finally, the nephrology community eagerly awaits the
results of the academic prospective randomized trial
PIVOTAL (launched by Kidney Research UK), which
began in the UK in 2013, with lead investigator Prof. Ian
Macdougall. This trial is comparing two iron therapy
strategies based on iron sucrose: the first is in keeping with
KDOQI 2006 and ERBP 2009 and is aimed at maintaining
ferritin[200 ng/mL and TSAT[20 %, while the second is
more liberal, with larger replenishment of iron stores
(ferritin up to 700 ng/mL and TSAT up to 40 %). A total of
2080 incident patients with a dialysis vintage of less than
1 year will be followed for 4 years in 55 UK centers [113].
The primary endpoint will be the time to all-cause death or
a composite of non fatal cardiovascular events (myocardial
infarction, stroke and hospitalization for heart failure)
[113]. This trial will not examine the possible benefit of
more physiological targets of iron replenishment advocated
by us and others [8, 9, 15, 16] and applied successfully in
Japan for a decade [21]. This will require a specific trial.
11 Conclusion
Iron overload was previously considered rare in hemodial-
ysis patients but is now an increasingly recognized clinical
situation. It is therefore possible that many cases of iron
overload in hemodialysis patients may in fact be owing to
iatrogenic hemosiderosis. Recent studies based on quanti-
tativeMRI suggest a strong link between the IV iron dose and
the risk of iron overload, and challenge both current iron
biomarker cutoffs and clinical guidelines, especially with
respect to recommended iron doses. In addition, some recent
long-term observational studies suggest that excessive IV
iron may increase mortality and cardiovascular events in
hemodialysis patients. This recently rediscovered adverse
effect of IV iron products has stimulated pathophysiological
and epidemiological studies, and has led to profound ongo-
ing changes in the concept of and clinical approach to IV iron
therapy in dialysis patients, with the overriding aim of
improving its safety.
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